Back to News
Apr 23, 2026 12:00 PM

Novo Nordisk Eyes Approval For Potential First Oral GLP-1 Diabetes Pill In Young Patients

Novo Nordisk A/S (NYSE:NVO) reported positive topline results from its late-stage PIONEER TEENS trial, showing that oral semaglutide significantly improved blood sugar control in children and adolescents with type 2 diabetes.

Oral Semaglutide Shows Superior Glycaemic Control

The phase 3a study evaluated oral semaglutide in patients aged 10–17 years and found the drug delivered a superior reduction in HbA1c (blood sugar levels) compared to placebo.

The trial demonstrated a statistically significant and superior reduction in blood sugar by 0.83% versus placebo at 26 weeks.

The treatment also demonstrated a safety profile consistent with prior semaglutide trials, reinforcing its tolerability.

Oral semaglutide is currently marketed as Rybelsus in the U.S. and Europe.

Novo Nordisk expects to file for regulatory approval of a label expansion for Ozempic pill and Rybelsus in the U.S. and EU in the second half of the year.